NCT05871541View on ClinicalTrials.gov

A First-in-Human Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

May 26, 2023

Primary Completion Date

March 25, 2024

Study Completion Date

March 25, 2024

Conditions
Herpes Zoster (HZ)ShinglesInfectious Disease
Interventions
BIOLOGICAL

JCXH-105

As IM injection

BIOLOGICAL

Active Control (Shingrix)

As IM injection

Trial Locations (3)

33024

CenExel RCA, Hollywood

33613

CenExel FCR, Tampa

08009

CenExel HRI, Berlin

Sponsors

Collaborators (1)

ICON plc
All Listed Sponsors
collaborator

ICON plc

INDUSTRY

lead

Immorna Biotherapeutics, Inc.

INDUSTRY

NCT05871541 - A First-in-Human Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vaccine | Biotech Hunter | Biotech Hunter